# Study of DF1001 in Patients With Advanced Solid Tumors

> **NCT04143711** · PHASE1,PHASE2 · COMPLETED · sponsor: **Dragonfly Therapeutics** · enrollment: 270 (actual)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** DF1001
- **DRUG:** Nivolumab
- **DRUG:** Nab paclitaxel
- **DRUG:** Sacituzumab Govitecan-hziy

## Key facts

- **NCT ID:** NCT04143711
- **Lead sponsor:** Dragonfly Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-11
- **Primary completion:** 2025-12-05
- **Final completion:** 2025-12-05
- **Target enrollment:** 270 (ACTUAL)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04143711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04143711, "Study of DF1001 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04143711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*